These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8128417)

  • 21. Requirements for publication of bioequivalence pharmacokinetic studies in Clinical Therapeutics.
    Schweers SA; Walson PD
    Clin Ther; 2009 Feb; 31(2):368-9. PubMed ID: 19302909
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics.
    Chen ML; Lee SC; Ng MJ; Schuirmann DJ; Lesko LJ; Williams RL
    Clin Pharmacol Ther; 2000 Nov; 68(5):510-21. PubMed ID: 11103754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioequivalence of topical dermatological dosage forms--methods of evaluation of bioequivalence. AAPS/FDA Workshop on 'Bioequivalence of Topical Dermatological Dosage Forms-- Methods of Evaluating Bioequivalence', September 4-6, 1996, Bethesda, Md.
    Shah VP; Flynn GL; Yacobi A; Maibach HI; Bon C; Fleischer NM; Franz TJ; Kaplan SA; Kawamoto J; Lesko LJ; Marty JP; Pershing LK; Schaefer H; Sequeira JA; Shrivastava SP; Wilkin J; Williams RL
    Skin Pharmacol Appl Skin Physiol; 1998; 11(2):117-24. PubMed ID: 9603663
    [No Abstract]   [Full Text] [Related]  

  • 25. [Are therapeutic drugs freely interchangeable? Studies of bioavailability and bioequivalence].
    Blume H
    Verh Dtsch Ges Inn Med; 1988; 94():411-9. PubMed ID: 3061214
    [No Abstract]   [Full Text] [Related]  

  • 26. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioequivalence assessment: a pharmaceutical industry perspective.
    Godbillon J; Cardot JM; Lecaillon JB; Lefevre G; Sioufi A
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):153-8. PubMed ID: 8839689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bioequivalence of generic drugs: sense and nonsense].
    Brune K; Dietzel K
    Fortschr Med; 1988 Nov; 106(33):16-7. PubMed ID: 3209169
    [No Abstract]   [Full Text] [Related]  

  • 30. Bioavailability and bioequivalence: average, population and/or individual.
    Colburn WA; Keefe DL
    J Clin Pharmacol; 2000 Jun; 40(6):559-60. PubMed ID: 10868304
    [No Abstract]   [Full Text] [Related]  

  • 31. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimum allocation of treatments for Welch's test in equivalence assessment.
    Dette H; Munk A
    Biometrics; 1997 Sep; 53(3):1143-50. PubMed ID: 9333344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Half-life revisited: implication in clinical trials and bioavailability/bioequivalence evaluation.
    Chen ML; Pelsor FR
    J Pharm Sci; 1991 Apr; 80(4):406-8. PubMed ID: 1865346
    [No Abstract]   [Full Text] [Related]  

  • 34. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levothyroxine dosage and the limitations of current bioequivalence standards.
    Hennessey JV
    Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756
    [No Abstract]   [Full Text] [Related]  

  • 36. Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group.
    Patnaik RN; Lesko LJ; Chen ML; Williams RL
    Clin Pharmacokinet; 1997 Jul; 33(1):1-6. PubMed ID: 9250419
    [No Abstract]   [Full Text] [Related]  

  • 37. Considerable cost savings through the analysis of pooled plasma samples in bioequivalence studies that fail to show bioequivalence.
    Hundt HK; Schall R; Luus HG; Müller FO
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):331-6. PubMed ID: 8370632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Truncated AUC evaluates effectively the bioequivalence of drugs with long half-lives.
    Endrenyi L; Tothfalusi L
    Int J Clin Pharmacol Ther; 1997 Apr; 35(4):142-50. PubMed ID: 9112134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What are narrow therapeutic index drugs?
    Levy G
    Clin Pharmacol Ther; 1998 May; 63(5):501-5. PubMed ID: 9630822
    [No Abstract]   [Full Text] [Related]  

  • 40. Sequential designs for equivalence studies.
    Whitehead J
    Stat Med; 1996 Dec; 15(24):2703-15. PubMed ID: 8981681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.